Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 1.80B |
| Revenue (ttm) | 44.05M |
| Net Income (ttm) | 1.60B |
| Shares Out | 54.31M |
| EPS (ttm) | 24.95 |
| PE Ratio | 1.33 |
| Forward PE | 2.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 520,182 |
| Open | 32.10 |
| Previous Close | 31.95 |
| Day's Range | 31.34 - 33.26 |
| 52-Week Range | 29.21 - 62.16 |
| Beta | 1.50 |
| Analysts | Buy |
| Price Target | 58.25 (+75.8%) |
| Earnings Date | Nov 3, 2021 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 58.25, which is an increase of 75.77% from the latest price.
News
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company's Strategic Vision in Genetically Define...
– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February –
4 Biotechs That Were Winners at ASH
Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that t...
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden
Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase (PK) deficiency. Data ...
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Bur...
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients –
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers...
– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated –
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Impr...
– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients –
Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
Agios Appoints Richa Poddar as Chief Commercial Officer
Darrin Miles to Depart Agios to Pursue a Chief Executive Officer Opportunity Darrin Miles to Depart Agios to Pursue a Chief Executive Officer Opportunity
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 –
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the co...
Agios To Present at September Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios' Rare Anemia Drug Application Under FDA Priority Review
The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agency's ...
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with...
-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU –
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that t...
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.